We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look ...

Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The pharmaceutical giant’s CEO mentioned this in the Q4 earnings call ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

A roundup of recent health-related developments includes Adani's partnership with Mayo Clinic for affordable healthcare in ...

Merck’s recent earnings call revealed that although the company generated worldwide sales of $64.2 billion—an 7% increase over 2023—the company will be temporarily suspending Gardasil shipments to ...